Brief: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand Into Five European Countries
27/02/2024 11:23
Feb 27 (Reuters) - Greenwich Lifesciences Inc GLSI.O :
* GREENWICH LIFESCIENCES FLAMINGO-01 PHASE III CLINICAL
TRIAL
APPROVED TO EXPAND INTO FIVE LARGEST EUROPEAN COUNTRIES
* GREENWICH LIFESCIENCES INC - APPLICATION TO EXPAND
FLAMINGO-01
INTO EUROPE HAS BEEN FORMALLY APPROVED BY SPAIN, FRANCE,
GERMANY, ITALY, AND POLAND
Source text for Eikon: ID:nGNX1L1GDl
Further company coverage: GLSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Greenwich Lifesciences
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Greenwich Lifesciences Inc reports results for the quarter ended June 30 - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Announces Approval To Expand FLAMINGO-01 Into The United Kingdom
U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio